ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, ZIOP is expected to report 3Q20 loss of $ 0.09 per share.
For the full year, analysts anticipate loss of $ 0.36 per share bottom line.
Stock Performance
Shares of ZIOPHARM Oncology Inc traded up $ 0.21 or 9.29 percent on Wednesday, reaching $ 2.47 with volume of 1.64 million shares. ZIOPHARM Oncology Inc has traded high as $ 2.48 and has cracked $ 2.24 on the downward trend
The closing price of $ 2.47, representing a 25.56 % increase from the 52 week low of $ 1.80 and a 59.71 % decrease over the 52 week high of $ 5.61.
The company has a market capital of $ 529.30 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
ZIOPHARM Oncology Inc will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ziopharm.com
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patients immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer.
